LCG
AEGR

Lisanti Capital Growth’s Aegerion Pharmaceuticals AEGR Stock Holding History

Lisanti Capital Growth’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-27,760
Closed -$2.38M – 139
2013
Q3 		$2.38M Buy
27,760
+8,145
+42% +$690K 1.08% 38
2013
Q2 		$1.8M Buy
+19,615
New +$1.04M 0.86% 57

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lisanti Capital Growth's AEGR Position: Q4 2013 in Review

Lisanti Capital Growth sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 27,760 shares — an estimated $2.38M sold.

Lisanti Capital Growth first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $2.38M in Q3 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Lisanti Capital Growth reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Lisanti Capital Growth sold 27,760 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $2.38M.
  • Lisanti Capital Growth first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Lisanti Capital Growth's Aegerion Pharmaceuticals position peaked at $2.38M in Q3 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Lisanti Capital Growth's 13F filing for Q4 2013, filed 29 Jan 2014.